Search Results
Your search for ,are matches 21906 pages
Showing 18601 - 18650Recent Reports and Perspectives on Chronic Lymphocytic Leukemia
Recent articles on developments and controversies in the treatment of chronic lymphocytic leukemia include the following features from The ASCO Post, which are also available at www.ascopost.com: “Recent FDA Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare ...
Linking Biology and Therapy in Chronic Lymphocytic Leukemia
Recent discoveries in biology, therapy, and (most importantly) the interplay between these two have led to groundbreaking advances in chronic lymphocytic leukemia (CLL). These advances underline the impact of the “translational” approach to cancer management in general. Standard of Care...
CLEOPATRA: Survival With Dual HER2 Blockade ‘Unprecedented’
In the final overall survival analysis of the phase III CLEOPATRA trial, HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the European Society for Medical...
Dr. Conti Replies
Dr. Watson states that my assertion that physicians gain profit from the administration of chemotherapy in private practice is “absurd.” Recent reports from the Oncology Circle practices [a data-sharing collaborative of best-in-class oncology practices from across the country] suggest that current...
More on Chemotherapy Costs
I took exception to a number of the comments made by Rena Conti, PhD, in The ASCO Post (“Health-Care Reform Is Changing the Oncology Landscape,” October 15, 2014, page 1). I realize that The ASCO Post is not a peer-reviewed and indexed publication, but as an ASCO member, I also recognize that the...
The 2014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, PhD, and Jointly to May-Britt Moser, PhD, and Edvard I. Moser, PhD
The 2014 Nobel Prize in Physiology or Medicine has been awarded with one half to John O’Keefe, PhD, of University College London, and the second half jointly awarded to May-Britt Moser, PhD, and Edvard I. Moser, PhD, of the Norwegian University of Science and Technology in Trondheim, for their...
Neoadjuvant Chemotherapy Plus Two Anti-HER2 Agents Optimal for HER2-Positive Breast Cancer
For women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, combining two anti-HER2 agents with chemotherapy is the most effective treatment modality in the neoadjuvant setting, according to a meta-analysis published in the Journal of the National Cancer Institute. The...
Effect of Micro-RNA on M2 Macrophages and Murine Glioblastoma
Monocyte-derived glioma-associated macrophages are the largest infiltrating immune cell population in glioblastomas and act to facilitate gliomagenesis. In a study reported in the Journal of the National Cancer Institute, Xu and colleagues assessed the effect of microRNA (miR)-142-3p on...
Sonic Hedgehog Factor GLI1 Induces Resistance to Cytarabine and Ribavirin in AML via Glucuronidation
Responses to cytarabine-based therapy in acute myeloid leukemia (AML) are often of short duration. Ribavirin has been used to inhibit the eukaryotic translation initiation factor (eIF4E) and has produced responses, including remissions, in AML, but relapse invariably occurs. As reported in Nature,...
DNA Double-Strand Break Repair Genes and Oxidative Damage in Brain Metastasis of Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Woditschka and colleagues identified a role for the DNA repair genes BARD1 and RAD51 and oxidative damage in brain metastases in breast cancer. The two genes were implicated in expression profiling of 23 matched resected brain...
Impressive Survival Data for Women With HER2-Positive Breast Cancer Increase First-Line Use of Pertuzumab/Trastuzumab
"Impressive,” “outstanding,” and “unprecedented” are among the terms used to describe the 56.5-month overall survival for women with HER2-positive metastatic breast cancer receiving first-line treatment with pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel in the...
Printed NCCN Guidelines for Patients Now Available Through Amazon.com
The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation, recently announced the availability of printed versions of the NCCN Guidelines for Patients for order on Amazon.com for the following cancer types: Breast (Stages 0–IV), Colon, and Pancreatic Cancers;...
Ramucirumab in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 5, 2014, ramucirumab (Cyramza) was approved for use...
The Power of Laughter
The following essay by Julie Vose, MD, MBA, FASCO, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories (May 2014), coedited by Stan Winokur, MD, and Vincent Coppola. The book is available on Amazon.com and thebigcasino.org. When I met Cindy, she was...
A Candidly Humorous Approach to the Cancer Journey
BOOKMARK Title: Shrinkage: Manhood, Marriage, and the Tumor That Tried to Kill MeAuthor: Bryan BishopPublisher: Thomas Dunne BooksPublication date: April 29, 2014Price: $25.99; hardcover, 336 pages At 30 years old, Bryan Bishop was having the time of his life. Known to millions of radio fans as...
A Father and Son’s Journey Through Medicine
BOOKMARK Title: The Good Doctor: A Father, a Son, and the Evolution of Medical EthicsAuthor: Barron H. Lerner, MDPublisher: Beacon PressPublication date: May 13, 2014Price: $25.95; hardcover, 240 pages One morning in 1996, an infectious disease specialist was making rounds when he and his team...
Acupuncture Treatment for Cancer Pain and Chemotherapy-Induced Peripheral Neuropathy
Acupuncture is a traditional Chinese medicine technique that involves inserting and manipulating filiform needles into specific points of the body to achieve a therapeutic effect. According to traditional Chinese medicine, disruptions in the flow of “vital energy” (qi) throughout the body are the...
Why Physician-Scientists Are Indispensable to Cancer Research
This is an exciting time for cancer research. We are beginning to see breakthroughs for patients with advanced melanoma, leukemia, multiple myeloma, lung cancer, and many other forms of cancer. Even so, cancer is projected to increase by about 45% and to become the leading cause of death in America ...
Institute of Medicine Elects 70 New Members, 10 Foreign Associates
The Institute of Medicine (IOM) has announced the names of 70 new members and 10 foreign associates during its 44th Annual Meeting held in October. Election to the IOM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Fast Facts About Metastatic Breast Cancer
According to the Metastatic Breast Cancer Network (mbcn.org): An estimated 155,000 Americans are currently living with metastatic breast cancer, and approximately 40,000 people (39,620 women and 410 men) will die from the disease this year. Between 6% and 10% of new breast cancer cases are...
Metastatic Breast Cancer Alliance Report Finds Research for the Disease Is Underfunded, Details Gaps in Patient Services
In October, the newly formed Metastatic Breast Cancer Alliance (MBCA) released its report, Changing the Landscape for People Living With Metastatic Breast Cancer, which details some disturbing findings. Following a yearlong analysis of 224 clinical trials, 2,281 funded research projects in...
Clinical Trials Actively Recruiting Patients With Colon or Rectal Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies of people with colon or rectal cancer in the newly diagnosed and metastatic settings. The studies include phase I, Ib, II, observational, and interventional trials investigating new drug...
Tina Lundgren Elected Chairman of the Ronald McDonald House New York Board of Directors
Ronald McDonald House® New York announced that Tina Lundgren has been elected to serve as Chairman of its Board of Directors. Mrs. Lundgren will succeed Stanley B. Shopkorn, Managing Director of Hilltop Park Associates LLC, who has served as chairman since 2006. Mrs. Lundgren will serve a 3-year...
2014 Ellen Stovall Award Presented to Giuliana Rancic, E! News Co-Anchor and Co-Host of The Fashion Police
As part of the Lilly Oncology On Canvas Art Competition, Lilly Oncology and the National Coalition for Cancer Survivorship created the Ellen Stovall Award in honor of Ellen Stovall, a tireless advocate for cancer survivors and former president and CEO of NCCS. The award recognizes those who use...
ASCO Endorses CAP/IASLC/AMP Guidelines for Molecular Testing of Patients With Non–Small Cell Lung Cancer
Personalized medicine is an established treatment concept for patients with advanced non–small cell lung cancer (NSCLC), and molecular characterization of tumors is crucial for choice of (first-line) therapy. As of right now, we have U.S. Food and Drug Administration (FDA)-approved drugs for two...
ASCO Endorses Guideline for Molecular Testing for Selecting Lung Cancer Patients for EGFR and ALK Inhibitor Treatment
ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor...
NIH Awards More Than $30 Million to Enhance Diversity in the Biomedical Research Workforce
The National Institutes of Health (NIH) announced the award of more than $30 million in fiscal year 2014 funds to develop new approaches that engage researchers, including those from backgrounds underrepresented in biomedical sciences, and prepare them to thrive in the NIH-funded workforce. These...
From the Genome to the Bedside: New Treatment Options for Children and Young Adults With Philadelphia Chromosome–Like ALL
The outcome for adolescents and young adults with acute lymphoblastic leukemia (ALL) is inferior to that in children, and the outcome for children with ALL who experience relapse is dismal. Therefore, new therapeutic options are urgently needed to improve survival rates for this high-risk ALL...
Kinase-Activating Alterations Identified in Most Cases of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia May Be Targetable With Available Tyrosine Kinase Inhibitors
In a study reported in The New England Journal of Medicine, Kathryn G. Roberts, PhD, of St. Jude Children’s Research Hospital, and colleagues performed detailed genomic analysis of patients with Philadelphia chromosome–like acute lymphoblastic leukemia (ALL) and identified kinase-activating...
Half of Premature Colorectal Cancer Deaths Due to Socioeconomic Inequality
Half of all premature deaths from colorectal cancer (described as deaths in people ages 25 to 64) in the United States are linked to ethnic, socioeconomic, and geographic inequalities, and therefore could be prevented according to a new study by American Cancer Society researchers. The report,...
The RAINBOW Trial: Dawn of a New Era in Upper Gastrointestinal Malignancies
As reviewed in this issue of The ASCO Post (page 155), the RAINBOW trial is an international phase III study demonstrating improved overall survival with ramucirumab (Cyramza) plus paclitaxel as second-line therapy for patients with advanced gastric/gastroesophageal junction adenocarcinoma over...
BRAF/MEK Inhibition in BRAF-Mutant Advanced Melanoma
Preliminary evidence of efficacy for BRAF inhibitors as monotherapy in advanced melanoma first emerged in 2009.1 Phase II and III trials rapidly ensued for vemurafenib (Zelboraf) and dabrafenib (Tafinlar), leading to U.S. Food and Drug Administration (FDA) approval in 2011. As a result of melanoma...
Expert Panel Explores Cost, Value, and Patient-Centered Care in Cancer Treatment
In assessing a cancer treatment, cost and value are two key factors. So how, the moderator asked, do they enter into your everyday decisions? Tanisha Carino, PhD, Executive Vice President of Avalere Health, was speaking to a clinical oncologist, a patient advocate, a pharma executive, and a health...
X-Ray of Metastatic Carcinoma of the Lungs, Washington, DC, 1924
One hundred years ago, primary lung cancer was considered a rarity, with only a few hundred cases acknowledged in the world literature. Until the middle of the 1920s, medical textbooks by noted authors continued to label the disease “rare,” although metastatic lung disease was recognized and...
Old Woman With Eye Tumor, circa 1878
This is a rare photograph of an older patient with a primary ocular tumor. These tumors are uncommon in old age so most photographs of retinoblastoma or rhabdomyosarcoma featured children. As a rule, there was no attempt to surgically remove these tumors and the children were only given supportive...
Expert Panels Offer Five Proposals to Address Challenges in Regulating, Implementing Next-Generation Sequencing
At the third annual Blueprint for Drug/Diagnostic Co-Development forum, cohosted by Friends of Cancer Research in Washington, DC, and the Alexandria Center for Life Science in New York, two panels tackled considerations in simultaneous development of drugs and companion diagnostics. Friends of...
Dying in America: Ensuring High-Quality Care at the End of Life
In September, the Institute of Medicine (IOM) released its report Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life. The report argues that the U.S. health-care system subjects patients to too many—and often futile—interventions near the end of life, often ...
New Century Health Appoints Dr. Andrew Hertler as Chief Medical Officer
New Century Health, a leading specialty management company focused on oncology and cardiovascular care, has announced that Andrew Hertler, MD, FACP, has joined its executive leadership team as the Chief Medical Officer. A highly experienced oncologist and physician executive, Dr. Hertler is one of...
High-Dose Melphalan, Early Stem Cell Transplant, and Lenalidomide Maintenance in Myeloma: One Size Still Does Not Fit All
In an important recent study by Dr. Antonio Palumbo and colleagues,1 reviewed in this issue of The ASCO Post (page 128), 273 patients aged ≤ 65 years were randomly assigned to early transplant or consolidation therapy using MPR (melphalan, prednisone, and lenalidomide [Revlimid]) after successful...
Addressing Patients’ Sexual Dysfunction Throughout Survivorship
Studies show that all cancers and related treatments have the potential to affect sexuality and sexual function. Surgery, chemotherapy, hormonal therapy, bone marrow transplantation, and radiation therapy can physically impact sexual health in myriad ways, including vaginal dryness, dyspareunia,...
NIH Awards Aim to Improve Understanding of Cell Pathways, Development of New Therapies
Building on a successful 3-year pilot project, the National Institutes of Health (NIH) has awarded more than $64 million to six individuals at five research institutions to create a database of human cellular responses—the Library of Integrated Network-based Cellular Signatures (LINCS)....
Pancreatic Cancer in 2014
Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in men and women in the United States. This year, about 46,000 people in this country will be diagnosed with pancreatic cancer, and more than 39,000 will die of the disease. The ASCO Post recently spoke with Margaret A....
Fixed-Combination Netupitant/Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 10, 2014, oral fixed-combination netupitant and...
ACCC to Develop Comprehensive Program on Immuno-Oncology for Community‐Based Providers
The Association of Community Cancer Centers (ACCC) has been provided with a contribution to develop a comprehensive program in immuno-oncology for community-based providers. The funding, provided by Bristol-Myers Squibb, will enable ACCC to establish the Institute for Clinical Immuno‐Oncology to...
Study Sheds Light on Factors That May Contribute to Pancreatic Cancer
New research that provides a better understanding of pancreatic cancer may help identify individuals at increased risk. The findings were recently published early online in Cancer.1 Pancreatic cancer is usually detected at a very late stage and has a 5-year survival rate of less than 5%. Strategies ...
FDA Approves Ramucirumab in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ramucirumab was approved in April 2014 as a single agent for the treatment of...
Top 10 Myths About FDA’s Office of Hematology and Oncology Products
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, FDA oncologists Gideon Blumenthal, MD, and Tatiana Prowell, MD, discuss 10 common myths about FDA’s Office of Hematology and Oncology ...
Bortezomib in Previously Untreated Mantle Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 9, 2014, bortezomib (Velcade) was granted approval for ...
U.S. Skin Cancer Costs Rise From 2002 Through 2011
The costs associated with skin cancer increased five times as fast as treatments for other cancers between 2002 and 2011, according to a Centers for Disease Control and Prevention (CDC) study published online in the American Journal of Preventive Medicine.1 The average annual cost for skin cancer...
Maintenance Therapy in Ovarian Cancer: What’s at Stake?
Maintenance therapy in ovarian cancer refers to a cohort of women achieving response to initial adjuvant chemotherapy who then go on to additional therapy in the hopes of extending time to recurrence or inducing a lasting remission. The concept is not new and retains its scientific and clinical...
